Premium
Management of recurrent gastrointestinal stromal tumors
Author(s) -
Winer Joshua H.,
Raut Chandrajit P.
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21890
Subject(s) - sunitinib , medicine , gist , sunitinib malate , imatinib , imatinib mesylate , tyrosine kinase inhibitor , stromal tumor , oncology , stromal cell , gastroenterology , cancer , myeloid leukemia
Recurrence after resection of primary gastrointestinal stromal tumor (GIST) is an unfortunately all‐too‐common phenomenon. The principal treatment for recurrent GIST is the first‐line tyrosine kinase inhibitor (TKI) imatinib mesylate. Those who progress on, or are intolerant of imatinib, are treated with second‐line TKI sunitinib malate. Cytoreductive surgery may be considered as an “adjuvant” therapy for patients with disease stabilized on imatinib, and, on an individual basis, sunitinib. J. Surg. Oncol. 2011; 104:915–920. © 2011 Wiley Periodicals, Inc.